RENO, Nev.--(BUSINESS WIRE)--Jan. 31, 2006--Lifeline Biotechnologies, Inc. (Pink Sheets: LBTN) today announced that the Company has successfully completed the initial testing of the OvaScope(TM) in surgical procedures. This micro endoscope has been designed by Lifeline Biotechnologies to be used by physicians to assist in the early detection of ovarian cancer. According to the Center for Disease Control (CDC) website, there are approximately 25,600. cases of ovarian cancers detected in the US each year. The unfortunate fact is that there is no FDA approved method for the early detection of ovarian cancer that is available to the medical community today. Consequently, ovarian cancer is not usually detected until the very late stages of the disease and at a time when treatments are less successful with only a 30% survival rate.
